Kumar, A, 375
Kurata, K, 54
Kuroki, Y, 549
Kurul, S, 58, 552
Kutlu, R, 425
Kuyucu, N, 104

Lacassie, Y, 504
La Mantia, I, 152
Landau, YE, 264
Landrieu, P, 401
Lang, AE, 325
Lang, S, 371
Lanham, DC, 463
Lanzi, G, 72
Larsen, PD, 868
Lasierra, R, 725
Lasker, AG, 348
Lee, DA, 64
Lee, JS, 119
Lee, Y-JM, 675
Leegwater, PAJ, 639
Legido, A, 150, 725, 851
Leonard, H, 481, 709
Leonard, S, 481
Lerman-Sagie, T, 258, 525, 876
Levisohn, P, 133
Lewis, AJ, 232, 367
Li, L, 828
Liapi-Adamidou, G, 113
Liebhaber, GM, 74
Lo, WD, 62
Logan, WJ, 499
Longaretti, F, 72
Lopez-Alberola, R, 64
Lozano, AM, 325
Lutz, R, 154

Mabie, A, 358
MacCollin, M, 718
MacGregor, DL, 98, 530, 714
Mackay, M, 165
Magariello, A, 269
Mahankali, S, 731
Makaronas, N, 113
Malhi, P, 174
Manaut, E, 879
Mancias, P, 572
Mannheim, GB, 450
Maria, B, 577, 578
Marie, SK, 235
Marshman, KC, 397
Massicotte, P, 420
Mastroyianni, SD, 570
Matalon, KM, 604, 611
Matalon, R, 604, 611, 809
Matsunaga, A, 147
Mattina, T, 79
Mavromatis, P, 570
Mazzei, R, 269
Mazzoni, E, 537
McAllister, J, 377
McDermott, C, 165
Meadows, T, 308
Meaney, BF, 180
Merlini, L, 537
Michelson-Kerman, M, 876
Michon, AM, 26
Mihailidou, H, 113
Miles, DK, 150
Milne, Y, 703
Milunsky, A, 413
Minassian, BA, 499
Minetti, C, 300, 537
Minshew, NJ, 317
Mitsudome, A, 549
Molina, IB, 741
Molinero, MR, 741
Mongini, T, 537
Moore, BD III, 731
Morandi, L, 537
Morgese, G, 306, 338
Mörk, SJ, 851
Moser, H, 578
Mostofsky, SH, 463
Muglia, M, 269
Mulhern, RK, 397
Mullaney, B, 688
Müllner-Eidenböck, A, 371
Munoz, S, 26
Muntoni, F, 191
Muriello, MA, 450
Musumeci, SA, 21
Muzik, O, 119

Nadell, JM, 504
Nagae-Poetscher, LM, *S25*
Nagata, J, 54
Naidu, S, 578, 646, 661, 662
Ndondo, AP, 343
Neufeld, MY, 525
Newschaffer, CJ, 463
Ng, Y, 307, 440
Nissenkorn, A, 876
Noachtar, S, 374
Numazaki, K, 296
Nunes, F, 718
Nunes, ML, 763
Nygaard, T, 812

Oakes, WJ, 496
Ochi, A, 247
Odabaş, D, 142, 494, 798
Odemis, E, 225
Ogawa, A, 549
Oguzkan, S, 68
Ohfu, M, 549
Okuyaz, Ç, 361, 394, 542
Oliveira, ASB, 235
Öner, AF, 798
Oresic, S, *S79*
Otsubo, H, 165, 247
Ouvrier, RA, 5
Owens, H, 17
Özyürek, H, 363

Pacheco, E, 356
Pakalnis, A, 772
Paolicchi, J, 772
Papacostas, SS, 432
Papazian, O, 356
Parano, E, 152
Parmeggiani, A, 1
Passoni, D, 21
Patitucci, A, 269
Pavkovic, I, 377
Pavone, P, 152
Payne, MS, 504
Perentes, E, 851
Pérez-González, JM, 725
Pevsner, J, 662
Pfund, Z, 119
Piccinelli, P, 21
Pinter, JD, 379
Posar, A, 1
Prescott, RJ, 703
Prior, TW, 62
Prokopiou, A, 113
Pronk, JC, 639
Pueyo, R, 845

Quattrone, A, 269

Rafay, M, 420
Raggi, ME, 21
Rasse, M, 371
Reddy, S, 675
Reed, UC, 235
Rho, JM, 39, 379
Riemann, E, 74
Riikonen, R, 693
Robb, SA, 298
Roberts, W, 165
Rodríguez, G, 725
Rohde, C, 662
Romeo, A, 21, 72
Romeo, G, 79
Ronen, GM, 180
Rooney, CM, 562
Rosenbaum, P, *S89*
Rosman, NP, 331, 450
Rossi, GA, 300
Roszkowski, M, 471
Rusin, J, 62
Rutka, JT, 247
Ryan, MR, 309

Saatci, U, 68
Sacco, O, 300
Sadeh, M, 876
Sakallioglu, AE, 68
Salladini, C, 306
Salman, MS, 220
Saltik, S, 241
Samper, MP, 725
Sanger, TD, *S9*
Santorelli, FM, 300
Sarac, K, 425
Sarnat, HB, 49, 776, 867
Saving, KL, 83
Sbyrakis, S, 113
Scaduto, MC, 1
Schaefer, B, 171
Scher, MS, 85, 155
Schiffmann, R, 443
Schor, NF, 127
Schwartz, RA, 471
Scott, J, 17
Sébire, G, 401
Şenbil, N, 104, 292
Senol, S, 109
Serdaroglu, A, 109, 361, 394, 542
Serra, A, 152
Shahar, E, 12
Shalev, RS, 264
Shen, C, 119
Shiihara, T, 147
Shin, M-S, 835
Shui, Q-X, 828
Sigirci, A, 425
Simeone, TA, 39
Sinclair, DB, 434
Singh, SP, 154
Singhal, BS, 646
Singhi, P, 174
Skardoutsou, A, 570
Skarpalezou, A, 113
Sladky, JT, 741
Slopis, JM, 731
Smeitink, J, 113
Smilari, P, 152
Smith, LH, 365
Smith, SD, 171
Smyth, DPL, 479
Smyth, P, 434
Snead, C III, 165, 247
Snook, RJ, 365
Sokol, DK, 365
Solari, A, 537
Sorge, A, 79
Soysal, S, 109
Spencer, FH, 5
Spilioti, M, 113
Sprovieri, T, 269
Stanger, M, *S79*
Stephens, D, 530
Stephenson, JBP, 816
Stickler, DE, 574
Straussberg, R, 258
Stump, MH, 463
Surendran, S, 604, 611, 809
Suzuki, K, 595
Swank, PR, 731
Szucs, S, 611

Tabarki, B, 140, 401
Tamir, A, 748
Tan, E, 76
Tardieu, M, 401
Tayem, H, 26
Tedeschi, G, 443
Teitell, B, 17
Tilton, AH, *S50*, 504
Timmerman, V, 76
Tirosh, E, 748
Tlili, K, 140
Tomoda, Y, 549
Tonoli, E, 300
Topaloglu, H, 76
Topçu, M, 437
Topper, L, 254
Trabelsi, A, 140
Trevathan, E, 374
Trigilia, T, 79
Tromp, SC, 407
Trotta, D, 306
Tsao, C-Y, 62
Tubbs, RS, 496
Tuncer, O, 142
Turanli, G, 363
Tyring, SK, 604, 611, 809

Umansky, R, 481
Üner, A, 798
Üner, Ç, 292

Urtizberea, A, 383

Vagiakou, EA, 570
Vainzof, M, 235
Vajsar, J, 375
Valencia, I, 725
Valencia, P, 356
Valenstein, ER, 574
Valseriati, D, 21
van der Knaap, MS, 639
vander Linden, I, 407
Vargas, AP, 429
Varghese, T, 767
Varon, D, 741
Vázquez-Cabrera, C, 429
Veggiotti, P, 72
Vendrell, P, 845
Ventura, P, 725
Verrotti, A, 306
Vining, EP, 228
Viollet, L, 383
Viri, M, 21, 72
Virta, A, 443
Vita, G, 537
Vivarelli, R, 338
Vlachonikolis, I, 113
Voudris, KA, 570
Vuong, A, 133

Waguespack, SG, 365
Walsh, L, 755
Watanabe, T, 93
Watemberg, N, 254, 258, 525, 876
Watson, JS, 481
Weaving, LS, 669
Webb, P, 703
Weber, JW, 407
Weinstock, A, 517
Weiss, S, 165, 247, 499
Werneck, LC, 235
Westall, CA, 220
Whyte, H, 530
Widdess-Walsh, P, 304
Wiesbauer, P, 371
Williams, LS, 800
Wilmshurst, JM, 343
Wilson, JL, 365
Wiltse, HE, 376
Wimmer, K, 371
Wong, V, 217
Wraige, E, 298
Wu, X-R, 131

Yacoub, M, 140
Yahav, Y, 254
Yakinci, C, 425
Yalnizoğlu, D, 437
Yamazaki, S, 93
Yasumoto, S, 549
Yelin, K, 356
Yetter, G, 376
Yoshikawa, H, 93, 424, 803

Zaccai, TF, 325
Zanoteli, E, 235
Zatz, M, 235
Zee, DS, 348
Zhao, Z-Y, 828

Subject Index

Absence seizures, 542–547
Acetylcholine receptors, 213–214, *S54*
ACTH, 165–169
Actin filaments, 204
Acute encephalopathy, 570–572
Acute flaccid paralysis, 741–746
Acute polyneuropathy, 574–576
Acute respiratory failure, 205
Acute transverse myelitis, 401–406
Adeli suit, *S93*
ADHD, 109–112, 264–268, 354, 394–396, 555–561, 653–660, 835–842
Adolescents, 133–138, 153, 205–206, 210, 555–561
A8344G mutation, 62–63
Afterdischarges, 247–253
Aging, 185–189
Alcohol, *S51–S52*
Alexander's disease, 586, 625–630
Alternative therapy, 714–716
Amino acids, 694, 696
Amyloid-β, 185–189
Andermann syndrome, 76–78, 199
Andersen's syndrome, 199
Anemia, 800–802
Anesthesia, *S60–S61*
Angelman's syndrome, 21–25
Angiography, 420–423
Angiomatosis, 35–38, 304–305
Animal models, 488–489
Antepartum events, 85–92
Antibiotics, 828–834
Antibodies, 212, 213–214
Antiepileptics, 331–337, 377, 552–553
Antiganglioside GM, 212
Anxiolytics, *S60–S61*
AOCCN, 131–132
Arabian Peninsula, 767–771
Arterial ischemic stroke, 530–536
Artery occlusion, 450–461
Ashworth Scale, 26–34
Asian and Oceanian Congress of Child Neurology, 131–132
Aspartoacylase, 604–609, 611–615
Asphyxia, 488–489
Astrocytomas, 859, 860
Ataxia, 309–315, *S8*, *S18–S19*, *S45–S46*
Ataxic neuropathy, 208
Atherosclerosis, 150–151
Athetosis, *S4*, *S43–S44*, *S75–S76*
Athlete, 205–206
Atonic seizures, 397–400
Atrophy, 147–149, 214, 269–271, 383–389, 537–541
Attention-deficit hyperactivity disorder, 109–112, 264–268, 354, 394–396, 555–561, 653–660, 835–842
Auditory neuropathy, 358–360
Auditory processing, 228–232
Autism, 113–117, 165–169, 317–323, 463–469, 488–489, 694, 696
Autoimmune myasthenia gravis, 211
Autosomal dominant disorder, 196–197, 209, 718–723
Autosomal dominant Emery-Dreifuss muscular dystrophy, 196–197
Autosomal dominant myotonia congenita, 209
Autosomal recessive spinal muscular atrophy, 269–271

Baclofen, 26–34, *S46*, *S47*, *S70–S74*, *S76*
Bacterial meningitis, 828–834
Ballism, *S16*, *S42–S43*
Balloon cells, 784
Barry-Albright Dystonia Scale, *S5*
Basal ganglia, 317–323, *S41–S42*
Basilar artery occlusion, 450–461
BDNF, 828–834
Becker muscular dystrophy, 192
Benzodiazepines, *S46*
β-thalassemia major, 798–799
β-tubulin isotype, 851–863
Bilateral dyskinetic cerebral palsy, 845–849
Bilateral footdrop, 212
Biperiden hydrochloride, 494–495
Birthweight, 491, 492
Bladder, 68–71
Blindness, 12–15
Bone fractures, 634
Bone histomorphometry, 698–702
Bone marrow transplant, 589
Botox, *S55–S61*, *S66*
Botulinum toxin, 493, *S53–S61*, *S66*
Bowel disease, 288–289
Bradykinesia, *S15–S16*
Brain, 85–92, 155–163, 441–442, 542–547, 683–687, 689–690, 857
Brain damage, 488–489
Brain-derived neurotrophic factor, 828–834
Brain injury, 513–515
Brainstem, 311
Brain stimulation, *S74*
Brief Assessment Examination, 819–827

Calcification, 296–297
Calderón-González, Raúl, 50–53, 82
Calpainopathy, 212
Canadian pediatric neurology services, 180–183
Canavan's disease, 584, 604–609, 611–615, 809–811
Cancer, 397–400, 858–860
Carbamazepine, 150–151, 552–553
Cardiac function, 191–200, 634
Cardiomyopathy, 192–193, 199
Casts, *S84–S85*
Cell cycle, 862
Cellular lineage, 776–784
Central nervous system, 39–45, 49, 210–211, 339–340, 634–635, 853–858
Central pontine myelinolysis, 292–295
Cerebellar ataxia, 309–315
Cerebellar atrophy, 147–149
Cerebellar disorders, 1–4, 147–149, 309–315, 463–469
Cerebellar hypoplasia, 1–4, 755–761
Cerebellar medulloblastomas, 857
Cerebellar neurogenesis, 855
Cerebellitis, 291–292
Cerebral abnormalities, 490
Cerebral angiography, 420–423
Cerebral cortex, 675–682
Cerebral edema, 144–146
Cerebral infarction, 298–300, 798–799
Cerebral palsy, 26–34, 174–178, 491, 493, *S31–S32*, *S33*, *S79–S86*, *S89–S94*, 845–849
Cerebral sinovenous thrombosis, 288–289
Cerebrotendinous xanthomatosis, 586, 633–637
Cerebrovascular disease, 714–716
Cerebrum, 54–57
Cesarean section, 489
Charcot-Marie-Tooth disease, 213
Chenodeoxycholic acid, 637
Chiari malformation, 496–498
Childhood Autism Rating Scale, 113–117
Chinese-Canadian children, 714–716
Cholesterol, 185–189
Cholinergic neurons, 690
Chorea, *S4*, *S6*, *S16*, *S42–S43*, *S76*
Chromatography, 269–271
Chronic inflammatory demyelinating polyradiculoneuropathy, 215
Chronic renal failure, 798–799
Churg-Strauss syndrome, 210–211
Class III β-tubulin isotype, 851–863
Coburn, Michael, 844
Cognitive function, 5–10, 407–412, 491, 492
Computed tomography, 98–102, 174–178, 542–547
Conduction, 214
Conductive education, *S92–S93*
Congenital glaucoma, 504–508
Congenital hearing loss, 171–173
Congenital muscular dystrophy, 197
Congenital myopathy, 198, 288
Congenital rubella syndrome, 296–297
Congestive heart failure, 211
Conners' Rating Scales, 109–112
Contralateral leptomeningeal angiomatosis, 304–305
Contralateral polymicrogyria, 232–234
Corpus callosum, 76–78, 291–292
Cortex, 675–682
Cortical development, 247–253, 340
Corticotropin, 165–169
Costello syndrome, 496–498
Cranial ultrasonography, 98–102
CT, 98–102, 174–178, 542–547
Cutaneous pretibial hemangioma, 225–228
Cysts, 646–651
Cytoskeletal protein, 851–863
Cytotoxicity, 597–598

Danon disease, 199
Dantrolene, *S46–S48*
Debrancher deficiency, 203, 205
Deep brain stimulation, *S74*
Delayed visual maturation, 358–360
Delta activity, 525–529
Demyelinating encephalomyelitis, 311
Demyelinating polyneuropathy, 206–207, 212, 215
Developmental disorders, 208, 264–268, 851–863
Diabetes mellitus, 365–367, 798–799
Diabetic ketoacidosis, 144–146
Diamond-Blackfan anemia, 800–802
Diet, 74–75, 113–117
Dilated cardiomyopathy, 192–193
Diplegia, *S28–S30*
Disability Scale, 325–330
Disequilibrium syndrome, 292–295
DNA, 62–63, 208
Down syndrome, 463–469
Duchenne muscular dystrophy, 17–19, 191–192
Dysembryoblastic neuroepithelial tumors, 860
Dyskinesia, 494–495
Dyskinetic cerebral palsy, 845–849
Dysphagia, 205
Dyssynchrony, 358–360
Dystonia, 325–330, *S2–S5*, *S13–S15*, *S33*, *S43–S44*, *S60*, *S72–S75*
Dystonia Rating Scale, 325–330
Dystrophinopathies, 79–80, 191–194
Dystrophy, 17–19, 191–200, 207, 209–210, 214
DYT1 gene, 325–330

Early-onset occipital idiopathic epilepsy, 72–74
Edema, 144–146
EEG, 12–16, 109–112, 174–178, 331–337, 394–396, 490, 517–529, 763–766, 878–879
eIF2B5 gene, 639–645
Electrical stimulation, *S84*, *S93*

Electroencephalogram, 12–16, 109–112, 174–178, 331–337, 394–396, 490, 517–529, 763–766, 878–879
Embryonal tumors, 858
Emery-Dreifuss muscular dystrophy, 195–197, 215–216
Encephalitis, 311, 356–358
Encephalocraniocutaneous lipomatosis, 725–728
Encephalofacial angiomatosis, 35–38
Encephalomyelitis, 311
Encephalopathy, 89–90, 205, 213, 290, 490, 570–572
Enterohepatic system, 634
Ependymal abnormalities, 784
Epilepsy, 1–4, 12–16, 109–112, 133–138, 150–151, 154, 165–169, 174–178, 272–284, 306, 307, 338–341, 407–412, 549–553, 763–766
Epileptic blindness, 12–15
Epileptiform discharges, 803–805
Evoked potentials, 383–390, 490
Excitatory amino acids, 694, 696
Excitatory glutamate synapses, 688–689
Exercise-induced ptosis, 205–206
Expert witnesses, 413–418
Extrapontine myelinolysis, 144–146, 292–295
Extrapyramidal cerebral palsy, *S*31–*S*32
Eye movement, 763–766

Facial malformations, 289–290, 304–305
Facioscapulohumeral muscular dystrophy, 198, 207, 210
Familial sensory ataxic neuropathy, 208
Familial spastic paraplegia, 140–141
Fasciculation, 204
FDA, 772–775
Fetal disorders, 85–92, 155–163
Fetal-maternal-placental disease, 85–92, 155–163
Fetal ultrasonography, 367–370
FK 506 tacrolimus, 206–207
Flaccid paralysis, 741–746
Focal segmental glomerulosclerosis, 147–149
Folinic acid, 562–569
Food and Drug Administration, 772–775
Footdrop, 212
49,XXXXY syndrome, 501–503
Fractures, 634
Fragile X syndrome, 463–469
Frontal intermittent rhythmic delta activity, 525–529
Fumarase deficiency, 289
Functional magnetic resonance imaging, 731–739

GABA, 21–25, 39–45, 49, *S*41–*S*42, *S*48
Gabapentin, 537–541, *S*48
Galactosylceramide, 597
Galloway-Mowat syndrome, 147–149
Gammopathy, 207
Ganglia, 317–323, *S*41–*S*42
Ganglionic acetylcholine receptors, 213–214
Genetics, 589, 598–599
Giant axons, 783–784
Giant cell astrocytoma, 859, 860
Giant cell granuloma, 371–373
Glaucoma, 504–508
Glial tumors, 861–862
Gliomas, 471–477, 858–860
Globoid cell leukodystrophy, 583, 595–602
Glomerulosclerosis, 147–149
Glucose metabolism, 119–125
Glutamate, 688–689
Glutamine, 154
Glycemic control, 365–367
Glycogen debrancher deficiency, 203, 205
Glycogen depletion, 876–877
Granuloma, 371–373
Gray matter, 119–125
Gross Motor Function Measure, *S*67–*S*77, *S*81–*S*82
Group A streptococcal infection, 434–436
Guillain-Barré syndrome, 204, 212, 741–746, 767–771

Hand, 481–486
Headache, 361–362, 394–396
Hearing loss, 171–173
Heart failure, 211
Hemangioma, 225–228
Hemidecorticectomy, 228–232
Hemimegalencephaly, 776–784
Hemiparesis, 363–364
Hemiplegia, *S*30–*S*31
Hemispherectomy, 290
Hemorrhagic meningoencephalitis, 289
Herpes encephalitis, 356–358
Histomorphometry, 698–702
HIV, 206
HMPAO, 542–547
Holoprosencephaly, 152
Honduras, 741–746
Human immunodeficiency virus, 206
Huntington's disease, 429–431
Hydatid disease, 343–346
Hydranencephaly, 367–370
Hydrocephalus, 312
Hydrogen peroxide neurotoxicity, 805–808
Hydrops fetalis, 89–90, 208
Hyperactivity, 109–112, 264–268, 354, 394–396, 555–561, 653–660, 835–842
Hyperbaric oxygen therapy, *S*92
Hyperkinesias, *S*42–*S*45
Hyperkinetic seizures, 517–524
Hypersomnic phase, 432–433
Hypertension, 440
Hyperthermia, 254–257
Hypoactive labyrinths, 171–173
Hypokinetic-rigid syndromes, *S*45
Hyponatremia, 207–208
Hypoplasias, 1–4, 220–225, 755–761
Hypoplastic cerebrum, 54–57
Hypotonia, 171–173, *S*19
Hypoxic-ischemic encephalopathy, 290, 490

ICNA, 786–794
ICNC, 131–132
Idiopathic epilepsy, 72–74
Idiopathic intracranial hypertension, 440
Imitrex, 772–775
Immunoglobulin, 204, 379–382, 767–771
Inclusion-body myositis, 185–189
Infantile Alexander's disease, 625–626
Infantile cerebrotendinous xanthomatosis, 633
Infantile Sandhoff's disease, 425–428
Infantile spasms, 165–169, 241–245, 374
Infants, 68–71, 204, 225–228, 258–262, 424–425, 441–442, 488–493, *S*32–*S*33, 748–754
Infarction, 298–300
Inflammatory bowel disease, 288–289
Inflammatory demyelinating polyneuropathy, 212, 215
Inflammatory myopathy, 288
Inflammatory response, 488
Injectable neuromuscular blockade, *S*50–*S*62
Inosiplex, 819–827
Insulin, 306, 365–367
Insulin neuritis, 365–367
Intelligence, 1–4
Interferon-α, 104–108, 819–827
Intermittent rhythmic delta activity, 525–529
International Child Neurology Association, 786–794
International Child Neurology Congress, 131–132
International Classification of Diseases-9th edition, 653–660
International Rett Syndrome Association, 709–712
Intra-arterial tissue plasminogen activator, 420–423
Intracranial calcification, 296–297
Intracranial hypertension, 440
Intrathecal baclofen, *S*70–*S*74, *S*76
Intravenous immunoglobulin, 379–382, 767–771
Intraventricular interferon-α, 819–827
Intron A, 819–827
Ion channelopathy, 199
Ischemic stroke, 530–536
Isoniazid, 142–143
Isoprinosine, 104–108, 819–827
Israeli infants, 748–754

JCN, 795–797
Joubert syndrome, 755–761
Journal of Child Neurology, 795–797
Juvenile Alexander's disease, 626
Juvenile-onset Leigh syndrome, 574–576
Juvenile spasms, 379–382

Kabuki make-up syndrome, 549–551
Kaplan-Meier survival rates, 819–827
Ketoacidosis, 144–146
Ketogenic diet, 74–75, 113–117
Kleine-Levin syndrome, 432–433
Knockout mouse, 604–609, 611–615
Krabbe's disease, 583, 595–602

Labyrinths, 171–173
Lactate, 290
Lafora's disease, 499–501
Lamivudine, 104–108
Lamotrigine, 133–138, 479–480
Lateralized epileptiform discharges, 803–805
Learning disorders, 394–396, 492, 835–842
Leg, 204
Leigh disease, 62–63
Leigh encephalopathy, 213
Leigh syndrome, 574–576
Lennox-Gastaut syndrome, 374
Leptomeningeal angiomatosis, 35–38, 304–305
Lesions, 291–292, 311, *S*75–*S*76
Leukodystrophies, 577–660
Leukoencephalopathy, 587–588, 646–651
Lewy bodies, 208–209
Limb-girdle muscular dystrophy, 193–194, 195
Limb-girdle muscular weakness, 203, 207
Lipomatosis, 725–728
Liquid chromatography, 269–271
Liver transplant, 206–207
Lobar holoprosencephaly, 152
Lower extremity weakness, 204–205, 210
Lymphoid cells, 675–682

Macrocephaly, 809–811
Magnetic resonance imaging, 64–67, 98–102, 119–125, 241–245, 317–323, 367–370, 463–469, 639–651, 731–739, 758–759, 805–808
Magnetic resonance spectroscopy, 290, 425–428, 443–449
Malignancy, 858–860
Malnutrition, 17–19
MCOLN1 gene, 443–449
MeCP2 gene, 661–691, 698–702
Medical expert witnesses, 413–418
Medical neuroscience teaching, 868–874
Medulloblastomas, 64–67, 857
Megalencephalic leukoencephalopathy, 587–588, 646–651
Meningitis, 828–834
Meningoencephalitis, 289
Mental retardation, 79–80, 199, 308, 376–377, 549–551
Mesial temporal sclerosis, 288, 340
Metabolism, 119–125
Metachromatic leukodystrophy, 583, 591–594

Methylenetetrahydrofolate reductase mutation, 800–802
Methylphenidate, 109–112
Microcephaly, 147–149
Microheterogeneity, 852
Micro syndrome, 54–57
Microtubules, 852
Migraine, 361–362
Mitochondrial DNA, 62–63, 208
Mitochondrial myopathy, 300–303
Mitochondrial transfer ribonucleic acid glutamic acid gene, 300–303
Möbius' syndrome, 210
Molecular biology, 39–45, 49
Molecular genetics, 598–599
Molecular weight, 675–682
Monoclonal gammopathy, 207
Monozygotic twins, 289, 504–508
Motor function, 204, 215, 312, 317–323, 348–354, 391–393, *S67–S77*, *S89–S94*
Movement disorders, 377, *S1–S94*, 878–879
Moyamoya disease, 361–362
MRI, 64–67, 98–102, 119–125, 241–245, 317–323, 367–370, 463–469, 639–651, 731–739, 758–759, 805–808
MRS, 290, 425–428, 443–449
Mucolipidosis, 443–449
Multifocal myoclonus, 434–436
Multitubulin hypothesis, 852
Multivoxel magnetic resonance spectroscopy, 425–428
Muscle biopsy, 213
Muscle disease, 213–214, 876–877
Muscle fibers, 204, 235–240
Muscle function, 635
Muscular atrophy, 269–271, 383–390, 537–541
Muscular dystrophy, 17–19, 191–200, 207, 210, 214, 215–216
Muscular weakness, 203–204, 206, 207
Myasthenia gravis, 211, 213–214, 375
Myelin, 597–598, 616–622
Myelination, 755–761, 783–784
Myelinolysis, 144–146, 292–295
Myelitis, 401–406
Myelodysplasia, 212–213
Myeloneuropathy, 212–213
Myocardial infarction, 150–151
Myocardium, 437–439
Myoclonus, 434–436, *S4*, *S6*, *S17*, *S44–S45*
Myofibrillar myopathies, 198–199
Myokymia, 572–574
Myopathies, 185–189, 191–200, 203, 207, 211, 235–240, 288, 300–303
Myositis, 185–189
Myotonia congenita, 209
Myotonic dystrophy, 197–198, 207, 209–210

***N*-acetylaspartic acid, 604–609, 611–615, 809–811**
***Naegleria fowleri*, 289**
Necrotizing encephalopathy, 570–572
Nemaline myopathy, 207, 211, 235–240
Neonatal arterial ischemic stroke, 530–536
Neonatal disorders, 85–92, 488–490
Neonatal herpes encephalitis, 356–358
Neonatal seizures, 562–569
Neonates, 290, 490, 588–589
Neoplasia, 861–863
Nerve atrophy, 214
Nerve conduction, 214
Nerve growth factor, 694, 696
Nervous systems, 39–45, 49, 210–211, 339–340, 634–635, 853–858
Neuritis, 365–367
Neuroaxonal disorders, 443–449
Neurobiology, 577, 851–863
Neuroblastic tumors, 857–858
Neurocysticercosis, 298–300
Neurodegenerative disease, 154
Neurodevelopmental disabilities, 84
Neuroepithelial tumors, 860
Neurofibromatosis, 68–71, 338–341, 348–354, 371–373, 471–477, 504–508, 718–723, 731–739
Neurogenesis, 855, 861
Neuroimaging, 58–61, *S25–S36*, 579–580
Neurological Disability Index, 819–827
Neuromuscular blockade, *S50–S62*
Neuromuscular diseases, 217–219
Neuronal tumors, 861–862
Neurons, 690
Neuropathy, 76–78, 206, 208, 358–360, 365–367, 851–863
Neuropsychological function, 491–492
Neuroscience, 441–442, 868–874
Neurosurgical treatment, *S67–S77*
Neurotoxicity, 805–808
Neurotrophic factors, 693–697, 828–834, 835–842, 845–849
Nevus, 304–305
***NF1* gene, 371–373**
Niikawa-Kuroki syndrome, 549–551
Noncompaction of myocardium, 437–439
Noonan's syndrome, 68–71
Nucleoside phosphorylase deficiency, 140–141
Nucleus basalis, 690

Occipital idiopathic epilepsy, 72–74
Ocular function, 634
Oculomotor function, 348–354
Oculopharyngeal muscular dystrophy, 214
Oligodendrogliomas, 859–860
Oligohydrosis, 254–257
Open lesions, *S75–S76*
Oppenheim's dystonia, 325–330
Opsoclonus, 356–358
Optic gliomas, 471–477
Optic nerve atrophy, 214
Oral pharmacotherapy, *S40–S48*
Orthostatic tremor, 204–205
Orthotic devices, *S84–S85*
Osteopenia, 698–702
Oxcarbazepine, 552–553
Oxidative phosphorylation, 876–877

Paclitaxel resistance, 863
Painter, Michael J., 127–130
Palsy, 26–34, 152, 174–178, 203, 491, 493, *S31–S33*, *S79–S86*, *S89–S94*, 741–746, 845–849
Panayiotopoulos syndrome, 307–308
Panencephalitis, 104–108, 363–364, 819–827
Papilledema, 215
Parainfluenza virus, 570–572
Paralysis, 26–34, 152, 174–178, 203, 491, 493, *S31–S33*, *S79–S86*, *S89–S94*, 741–746, 845–849
Paraneoplastic cerebellar syndromes, 312
Paraplegia, 140–141, 616–622
Paresis, 210
Paretic ataxia, 312
Parkinsonism, 812–815
Partial seizures, 331–337, 763–766
PEDI, 26–34
Pediatric Evaluation of Disability Inventory, 26–34
Pelizaeus-Merzbacher disease, 584–585, 616–622
Perinatal stroke, 800–802
Periodic lateralized epileptiform discharges, 803–805
Peripheral nervous system, 210–211, 635
Peripheral neuropathy, 76–78
PET, 119–125
Peto method, *S92–S93*
Pharmacotherapy, *S40–S48*
Phenol, *S52–S53*
Phenytoin, 494–495
Phonologic processing, 731–739
Phosphorylase deficiency, 140–141
Phosphorylation, 862–863, 876–877
Photosensitivity, 432–433
Pleomorphic xanthoastrocytoma, 860
Poliomyelitis, 214
Polish suit, *S93*
Polyglucosan body disease, 208–209
Polymicrogyria, 232–234
Polyneuropathy, 206–207, 212, 215, 574–576
Pontocerebellar hypoplasia, 220–225
Positron emission tomography, 119–125
Potentials, 383–390, 490
Prednisone, 203–204
Pregnancy, 204
Preterm infants, 488–493
Pretibial hemangioma, 225–228
Procainamide, 209–210
Protein, 185–189, 851–863
Protein tyrosine phosphatase, 211
Proton magnetic resonance spectroscopy, 443–449
Psychiatric issues, 1–4
Psychogenic disorders, *S19*
Psychopharmacology, 153
Psychosine, 597–598
Ptosis, 205–206
Pulmonary function, 634
Purine nucleoside phosphorylase deficiency, 140–141

Quadriplegia, *S30*
Quality of life, 491

Rapid eye movement, 763–766
Refractory epilepsy, 763–766
Refractory status epilepticus, 290
Regulatory disorders, 748–751
REM, 763–766
Renal failure, 798–799
Renal function, 798–799
Respiratory failure, 205, 209–210, 300–303
Retardation, 79–80, 199, 308, 376–377, 549–551
Retinoblastomas, 857
RettBASE, 709–712
Rett syndrome, 74–75, 481–486, 661–712
Rey-Osterreith Complex Figure, 835–842
Rhabdomyosarcoma, 68–71
Rhizotomies, *S68–S70*, *S75*
Rhombencephalosynapsis, 225–228
Rhythmic delta activity, 525–529
Ribonucleic acid, 828–834
Right hemisphere syndrome, 264–268
Rigidity, *S8*, *S15–S16*, *S45*
RNA, 828–834
Rod distribution, 235–240
Rodent, 689–690
Rubella syndrome, 296–297

Saccades, 348–354
Sandhoff's disease, 425–428
Saposin A, 599–601
Sarcoglycanopathies, 194–195
Sarcolemmal excitability, 211
Schilder's disease, 58–61
Schizencephaly, 232–234
Sclerosing panencephalitis, 104–108, 363–364, 819–827
Sclerosis, 288, 340, 844
Scoliosis, 703–707
Segmental glomerulosclerosis, 147–149
Seizures, 331–337, 397–400, 407–412, 517–524, 542–551, 562–569, 763–766
Sensory ataxia, 208, 312
Sensory conduction, 214
Serum carnitine, 552–553
Serum paraprotein, 215

"Setting sun" phenomenon, 424–425
Shaken baby syndrome, 83–84
Silent stroke, 798–799
Single photon emission computed tomography, 542–547
Sinovenous thrombosis, 288–289, 530–536
Sjögren's syndrome, 215
Sleep disorders, 394–396, 441, 763–766
SMN gene, 269–271
Sonospectrographic abnormalities, 492
Spasms, 165–169, 241–245, 374, 379–382
Spastic cerebral palsy, 26–34, 845–849
Spastic diplegia, *S*28–*S*30
Spastic hemiplegia, *S*30–*S*31
Spasticity, 208, 493, *S*10–*S*13, *S*25–*S*36, *S*46–*S*48, *S*50–*S*62, *S*67–*S*77, *S*89–*S*94
Spastic paraplegia, 140–141, 616–622
Spastic quadriplegia, *S*30
SPECT, 542–547
Spectroscopy, 290, 425–428, 443–449, 758–759
Spinal disease, 269–271, 343–346
Spinal muscular atrophy, 269–271, 383–390, 537–541
Spinobulbar paralysis, 203
Splenium, 291–292
Splints, *S*84–*S*85
SSPE, 104–108, 363–364, 819–827
Status epilepticus, 142–143, 290, 876–877
Stem cell therapy, 589–590
Stereotactic lesions, *S*76
Stimulation, *S*84, *S*93
Streptococcal infection, 434–436
Stroke, 312, 437–439, 530–536, 714–716, 798–802
Sturge-Weber syndrome, 35–38, 119–125, 304–305, 509–515
Subacute sclerosing panencephalitis, 104–108, 363–364, 819–827
Subcortical cysts, 646–651
Subependymal giant cell astrocytomas, 859, 860
Sumatriptan, 772–775
Survival motoneuron gene, 269–271
Synapses, 688–689
Syncope, 394–396
Syringomyelia, 212

Tacrolimus, 206–207
T cell, 211
Tc-HMPAO, 542–547
Telencephalic development, 855–856
Temporal sclerosis, 288, 340
Thalassemias, 798–799
Therapeutic riding, *S*84
Thrombosis, 288–289, 420–423, 530–536
Thymectomy, 375
Thymoma, 213–214
Tic disorders, 394–396, *S*6–*S*7, *S*16–*S*17, *S*44, 835–842
Tissue plasminogen activator, 420–423
Tizanidine, *S*46, *S*48
T14687C mutation, 300–303
Topiramate, 254–257, 258–262
Tourette syndrome, *S*44
Toxic cerebellar syndromes, 311
Toxic parkinsonism, 812–815
Transcriptional regulation, 862
Transfusion, 367–370
Transplantation, 206–207, 589
Transverse myelitis, 401–406
Trauma, 312
Treadmill training, *S*83
Tremor, 204–205, *S*7–*S*8, *S*17–*S*18, *S*45, *S*76
Trigeminal myokymia, 572–574
Tuberous Sclerosis Alliance, 844
Tubulins, 851–863, 867
Tumors, 339–340, 851–863
Twins, 289, 367–370, 504–508

Ultrasonography, 98–102, 367–370
Umbilical cord, 232–234
Urinary bladder, 68–71

Vacuolar myopathy, 199
Vacuolating leukoencephalopathy, 587–588
Valproate, 133–138, 306
Vanishing white matter disease, 586–587, 639–645
Vermian abnormalities, 463–469, 755–761
Vertebral artery occlusion, 450–461
Vigabatrin, 165–169
Visual impairment, 358–360, 491
Vitamin K, 93–97
Vitamin therapy, 376
Vocal cord palsy, 152

Walking, 530–536
Wallace, Sheila, 816–817
Weakness, 79–80, *S*19–*S*20
Weight, 133–138, 306
West Nile Virus infection, 214
White matter, 119–125, 586–587, 639–645
World Health Organization, *S*79, 767

Xanthoastrocytoma, 860
Xanthomas, 634
Xanthomatosis, 586, 633–637
X-linked dilated cardiomyopathy, 192–193
X-linked dominant Charcot-Marie-Tooth disease, 213
X-linked Emery-Dreifuss muscular dystrophy, 195–196
X-linked vacuolar myopathy, 199
Xp21-23 deletion, 79–80

PEDIATRIC NEUROLOGIST

The Department of Pediatrics of the University of Arkansas for Medical Sciences located at Arkansas Children's Hospital in Little Rock, Arkansas, is seeking candidates for a faculty position in the Section of Pediatric Neurology. Board eligibility or board certification in Neurology with special competence in Child Neurology is required. Candidates at any rank will be considered as well as candidates with a focus in education or research. The section is an accredited Pediatric Neurology Residency Program. Arkansas Children's Hospital is among the largest children's hospitals in the United States. The Department of Pediatrics employs over 150 faculty members and 75 residents. The Neurology section provides care for approximately 7000 outpatients, 2800 inpatient care days, and performs 3000 EEGs, 300 CCU EEG monitoring days and 500 Video EEG days, as well as, over 1700 other procedures per year. The Department has one of 14 fully accredited Pediatric Sleep Centers in the United States. Excellent new research lab facilities are available at the Arkansas Children's Hospital Research Institute. Starting date is negotiable, but the position is available immediately. Located in the foothills of the Ozark Mountain Range, Little Rock offers the "just right" combination of big city and hometown America, with incomparable, convenient outdoor and family activities.
For more information regarding, see the Department's web site: http://pediatrics.ach.uams.edu.

Interested individuals should contact:

Michele Moss, MD
Professor and Vice Chairman of Pediatrics
Arkansas Children's Hospital
800 Marshall St.
Little Rock, AR 72202
Phone: 501-364-1479
FAX: 501-364-3667
E-mail: mossmichele@uams.edu

The State of Arkansas has a Conrad 30 program and the University of Arkansas for Medical Sciences is an equal opportunity employer.

Pediatric Neurologist

Pediatric Neurologist, The University of Arizona, Tucson, AZ. Position for Asst/Assoc Prof/Prof of Clinical Pediatrics in the Department of Pediatrics Section of Neurology is available for a MD or DO with a commitment to resident education and inpatient and outpatient clinical care. Excellent core biomedical and molecular biological research facilities are available to faculty at the Steele Memorial Children's Research Center with competitive benefits package and is located in the beautiful southwest, with opportunity for year-round outdoor activities. For more information see Job# 993700 at www.hr.arizona.edu. Please submit CV with letter of interest to:

Fayez K. Ghishan, MD,
Professor and Head, Department of Pediatrics,
1501 N Campbell Avenue, PO BOX 245073,
Tucson, AZ 85724.

Initial application review began 8/14/01 and continues until position is filled.

The University of Arizona is an EEO/AA Employer-M/W/D/V.